Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 6 (2010), Issue 12 (December)

1. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.
   Nat Rev Drug Discov, 9(12): 929-39. [Abstract] [Full-text]
2. Accelerating orphan drug development.
   Nat Rev Drug Discov, 9(12): 901-2. [Abstract] [Full-text]
3. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
   J Pathol, 223(1): 15-27. [Abstract] [Full-text]
4. Serendipitous discovery of α-hydroxyalkyl esters as β-lactamase substrates.
   Biochemistry, 49(49): 10496-506. [Abstract] [Full-text]
5. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
   Cancer Cell, 18(6): 548-51. [Abstract] [Full-text]
6. Rational design of a selective covalent modifier of G protein βγ subunits.
   Mol Pharmacol, 79(1): 24-33. [Abstract] [Full-text]
7. Rational design of a selective covalent modifier of G protein βγ subunits.
   Mol Pharmacol, 79(1): 24-33. [Abstract] [Full-text]
8. Rational design of a selective covalent modifier of G protein βγ subunits.
   Mol Pharmacol, 79(1): 24-33. [Abstract] [Full-text]
9. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
   J Pharmacol Exp Ther, 336(1): 38-46. [Abstract] [Full-text]
10. Productivity shortfalls in drug discovery: contributions from the preclinical sciences?
    J Pharmacol Exp Ther, 336(1): 3-8. [Abstract] [Full-text]
11. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
    J Pharmacol Exp Ther, 336(1): 38-46. [Abstract] [Full-text]
12. Productivity shortfalls in drug discovery: contributions from the preclinical sciences?
    J Pharmacol Exp Ther, 336(1): 3-8. [Abstract] [Full-text]
13. Pharmacogenomics: will the promise be fulfilled?
    Nat Rev Genet, 12(1): 69-73. [Abstract] [Full-text]
14. Chemical modulators of autophagy as biological probes and potential therapeutics.
    Nat Chem Biol, 7(1): 9-17. [Abstract] [Full-text]
15. Pharmacogenomics: will the promise be fulfilled?
    Nat Rev Genet, 12(1): 69-73. [Abstract] [Full-text]
16. Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.
    Nat Chem Biol, 7(1): 22-4. [Abstract] [Full-text]
17. Recommendations for the validation of flow cytometric testing during drug development: II assays.
    J Immunol Methods, 363(2): 120-34. [Abstract] [Full-text]
18. Recommendations for the validation of flow cytometric testing during drug development: I instrumentation.
    J Immunol Methods, 363(2): 104-19. [Abstract] [Full-text]
19. Chemical modulators of autophagy as biological probes and potential therapeutics.
    Nat Chem Biol, 7(1): 9-17. [Abstract] [Full-text]
20. Pharmacogenomics: will the promise be fulfilled?
    Nat Rev Genet, 12(1): 69-73. [Abstract] [Full-text]
21. Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.
    Nat Chem Biol, 7(1): 22-4. [Abstract] [Full-text]
22. Recommendations for the validation of flow cytometric testing during drug development: II assays.
    J Immunol Methods, 363(2): 120-34. [Abstract] [Full-text]
23. Recommendations for the validation of flow cytometric testing during drug development: I instrumentation.
    J Immunol Methods, 363(2): 104-19. [Abstract] [Full-text]
24. A curricular divide: basic pharmacology vs. clinical pharmacology.
    Clin Pharmacol Ther, 89(1): 24-6. [Abstract] [Full-text]
25. A concise display of multiple end points for benefit-risk assessment.
    Clin Pharmacol Ther, 89(1): 56-9. [Abstract] [Full-text]
26. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.
    Clin Pharmacol Ther, 89(1): 75-80. [Abstract] [Full-text]
27. Pharmacologic development of male hormonal contraceptive agents.
    Clin Pharmacol Ther, 89(1): 133-6. [Abstract] [Full-text]
28. A curricular divide: basic pharmacology vs. clinical pharmacology.
    Clin Pharmacol Ther, 89(1): 24-6. [Abstract] [Full-text]
29. A concise display of multiple end points for benefit-risk assessment.
    Clin Pharmacol Ther, 89(1): 56-9. [Abstract] [Full-text]
30. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.
    Clin Pharmacol Ther, 89(1): 75-80. [Abstract] [Full-text]
31. Pharmacologic development of male hormonal contraceptive agents.
    Clin Pharmacol Ther, 89(1): 133-6. [Abstract] [Full-text]
32. A rapid vesicle electrokinetic chromatography method for the in vitro prediction of non-specific binding for potential PET ligands.
    J Pharm Biomed Anal, 54(4): 722-9. [Abstract] [Full-text]
33. A rapid vesicle electrokinetic chromatography method for the in vitro prediction of non-specific binding for potential PET ligands.
    J Pharm Biomed Anal, 54(4): 722-9. [Abstract] [Full-text]
34. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.
    Dig Dis Sci, 56(1): 115-24. [Abstract] [Full-text]
35. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.
    Dig Dis Sci, 56(1): 115-24. [Abstract] [Full-text]
36. Insights into radicicol biosynthesis via heterologous synthesis of intermediates and analogs.
    J Biol Chem, 285(53): 41412-21. [Abstract] [Full-text]
37. New approaches to neuroprotective drug development.
    Stroke, 42(1): S24-7. [Abstract] [Full-text]

© 2005-2013 Pharmacology Research Today. All Rights Reserved.